PBLS · NASDAQ
Parabilis Medicines (PBLS) Stock Price & Fundamentals
Parabilis Medicines (PBLS) closed at $679.09 on Oct 9, 2026, down 0.44% from the previous close of $682.09.
Share price, past year
1Y +5.21%Monthly closing prices
| Date | Close |
|---|---|
| Oct 9, 2026 | $679.09 |
| Sep 30, 2026 | $705.69 |
| Aug 31, 2026 | $707.84 |
| Jul 31, 2026 | $695.62 |
| Jun 30, 2026 | $684.53 |
| May 29, 2026 | $634.47 |
| Apr 30, 2026 | $657.38 |
| Mar 31, 2026 | $644.65 |
| Feb 27, 2026 | $666.07 |
| Jan 30, 2026 | $655.41 |
| Dec 31, 2025 | $664.14 |
| Nov 28, 2025 | $655.52 |
| Oct 31, 2025 | $630.31 |
Key statistics
- Market cap
- $82.81B
- P/E (TTM)
- —
- EPS (TTM)
- —
- Revenue (TTM)
- —
- Net income (TTM)
- —
- Shares outstanding
- 121.9M
- Dividend yield
- —
- 52-week range
- $615.67 – $719.98
Parabilis Medicines's market cap is $82.81B, based on a share price of $679.09 and 121.9M shares outstanding as of Jun 30, 2026.
Financials
| Quarter | Revenue | Net income | EPS (diluted) |
|---|---|---|---|
| Q2 FY2026ended Jun 30, 2026 | $148.00K | −$52.46M | −$2.32 |
| Q1 FY2026ended Mar 31, 2026 | $0.00 | −$45.32M | −$6.54 |
| Q2 FY2025ended Jun 30, 2025 | $0.00 | −$34.81M | −$22.28 |
| Q1 FY2025ended Mar 31, 2025 | $0.00 | −$38.33M | −$23.85 |
Earnings
Parabilis Medicines lost $2.32 per share in fiscal Q2 2026, reported Aug 13, 2026, compared with a loss of $22.28 a year earlier.
Diluted earnings per share by quarter
| Quarter | Reported | EPS (diluted) | A year earlier | Change |
|---|---|---|---|---|
| Q2 FY2026ended Jun 30, 2026 | Aug 13, 2026Earnings release | −$2.32 | −$22.28 | — |
| Q1 FY2026ended Mar 31, 20266 months minus last 3 months | — | −$6.54 | −$23.85 | — |
| Q2 FY2025ended Jun 30, 2025 | — | −$22.28 | — | — |
| Q1 FY2025ended Mar 31, 20256 months minus last 3 months | — | −$23.85 | — | — |
About Parabilis Medicines
- Name
- Parabilis Medicines, Inc.
- Ticker
- PBLS
- Exchange
- NASDAQ
- Industry (SEC SIC)
- Pharmaceutical Preparations
- Headquarters
- 30 Acorn Park Drive, 6th Floor, Cambridge, MA 02140
- Incorporated in
- Delaware
- Fiscal year ends
- December
- SEC CIK
- 0001657677
Recent SEC filings
- Sep 15, 2026
- Sep 2, 2026
- Aug 25, 2026
- Aug 13, 2026
- Aug 13, 2026
- Jun 11, 2026
ETFs that hold Parabilis Medicines
Of the ETFs and funds on Laurel, Vanguard Morningstar Total Stock Market ETF (VTI) holds the most Parabilis Medicines shares by value: 0.00% of the fund, as of its latest report to the SEC.
Frequently asked questions
What is Parabilis Medicines's stock price?
Parabilis Medicines (PBLS) closed at $679.09 on Oct 9, 2026, down 0.44% from the previous close of $682.09.
What is Parabilis Medicines's market cap?
Parabilis Medicines's market cap is $82.81B, based on a share price of $679.09 and 121.9M shares outstanding as of Jun 30, 2026.
Sources and methodology
Fundamentals come from Parabilis Medicines, Inc.'s filings with the SEC (EDGAR XBRL company facts). Fourth-quarter figures that companies don't report separately are calculated as the fiscal year minus the first three quarters. Trailing twelve-month (TTM) figures sum the latest four quarters. Prices are generated sample data for development. Last updated Oct 10, 2026. Data sources and disclosures